Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio) released an updated list of directors and committee assignments dated 26 June 2026.

The Board now consists of 14 members: seven executive directors, two non-executive directors and five independent non-executive directors. Key positions are held by:

• Chairman and Legal Representative: Mr. Xiong Jun • Vice Chairman: Dr. Li Ning • Chief Executive Officer and General Manager: Dr. Zou Jianjun • Co-Chief Executive Officer: Mr. Li Cong

Five specialised committees remain in place, each led by an experienced director:

1. Audit Committee – chaired by independent non-executive director Mr. Li Zhongxian. 2. Nomination Committee – chaired by independent non-executive director Dr. Feng Xiaoyuan. 3. Remuneration and Appraisal Committee – chaired by Mr. Li Zhongxian. 4. Strategic and ESG Committee – chaired by Mr. Xiong Jun. 5. Compliance Committee – chaired by independent non-executive director Ms. Lu Kun.

Other directors serve as members across the committees to provide oversight on audit, governance, remuneration, strategy and compliance matters. The updated structure underscores Junshi Bio’s emphasis on balanced governance, independent oversight and strategic planning as the company continues to develop its biopharmaceutical portfolio.